Drug Profile
Research programme: parasitic disease therapeutics - MabVax/Swiss Tropical and Public Health Institute
Latest Information Update: 10 Oct 2014
Price :
$50
*
At a glance
- Originator Telik
- Developer MabVax Therapeutics; Swiss Tropical and Public Health Institute
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parasitic infections
Most Recent Events
- 10 Oct 2014 No development reported for Parasitic infections in USA and Switzerland (unspecified route)
- 02 Nov 2010 Telik receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
- 31 Oct 2008 Early research in Parasitic infections in Switzerland (unspecified route)